EMA/368499/2015

European Medicines Agency decision

P/0133/2015

of 12 June 2015

on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP02-09-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 7523 70405555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0133/2015

of 12 June 2015

on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP02-09-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/106/2011 issued on 4 May 2011 and the decision P/0138/2013 issued on 21 June 2013,

Having regard to the application submitted by PTC Therapeutics International Limited on 2 March 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 22 May 2015, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ataluren (Translarna), granules for oral suspension, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This agreed paediatric investigation plan covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/83/2009 issued on 15 May 2009, including subsequent modifications thereof.

Article 3

This decision is addressed to PTC Therapeutics International Limited, 77 Sir John Rogerson's Quay, Dublin 2, Ireland.

Done at London, 12 June 2015

For the European Medicines Agency
Jordi Llinares Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/154775/2015
London, 22 May 2015

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000115-PIP02-09-M02

Scope of the application

Active substance(s):

Ataluren

Invented name:

Translarna

Condition(s):

Treatment of cystic fibrosis

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Granules for oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

PTC Therapeutics International Limited

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 7523 70405555
Contact EMA www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, PTC Therapeutics International Limited submitted to the European Medicines Agency on 2 March 2015 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/106/2011 issued on 4 May 2011, and the decision P/0138/2013 issued on 21 June 2013.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 24 March 2015.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition: treatment of cystic fibrosis

The waiver applies to:

- neonates from birth to less than 28 days of age;
- granules for oral suspension, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan

2.1. Condition: treatment of cystic fibrosis

2.1.1. Indication(s) targeted by the PIP

Treatment of cystic fibrosis due to nonsense mutation (nmCF)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Granules for oral suspension

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	1	Study 1: Age appropriate formulation and dosing device that allows accurate dosing for children weighing less than 20 kg.
Non-clinical studies	3	Study 2: 7-day tolerability and pharmacokinetic study of ataluren in neonatal Beagle dogs Study 3: 28-day dose range finding juvenile toxicology and toxicokinetic Study of ataluren in Beagle Dogs Study 4: 3-Month Juvenile Toxicology and Toxicokinetic Study of ataluren in Beagle Dogs with a 3-Month Recovery Period
Clinical studies	5	Study 5: Open-label, randomized, dose-ranging, challenge-dechallenge-rechallenge evaluation of pharmacodynamic (PD) activity, safety, and pharmacokinetics of ataluren. Study 6: Randomised, double-blind, placebo-controlled study to evaluate efficacy of ataluren adult and paediatric nmCF patients,

		≥6 years of age Study 7: Open-label extension study to evaluate safety of ataluren in adult and paediatric nmCF patients, ≥6 years of age. Study 8: Open label, multiple dose trial to evaluate the pharmacokinetics (PK), safety and pharmacodynamic (PD) effect of ataluren in paediatric patients with nmCF aged from 2 to less than 6 years. Study 9: Open label, multiple dose trial to evaluate the pharmacokinetics (PK) and safety of ataluren in paediatric patients with nmCF aged from 28 days to less than 23 months.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2019
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Duchenne muscular dystrophy

Authorised indication(s):

- Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older.

Authorised pharmaceutical form(s):

Granules for oral suspension

Authorised route(s) of administration:

Oral use